BioPharma Dive August 13, 2025
The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.
The Trump administration recently added to an ongoing push to boost pharmaceutical manufacturing in the U.S., launching a new program dubbed PreCheck that aims to ease the process of bringing domestic facilities online.
Using a two-phase approach, the program offers drug companies more frequent communication with the agency in early stages and streamlines development through pre-application meetings and early feedback in “the chemistry, manufacturing and controls section of the application,” the FDA said in its Aug. 7 announcement.
PreCheck is the latest move from the Trump administration to reduce overseas reliance on drugs, stemming from an executive order in May...
Today's Sponsors
Today's Sponsor